The early findings presented showed an overall response rate of 28 percent with pembrolizumab in patients with tumours that expressed PD-L1. Additionally, 48 percent of patients had stable disease, resulting in a disease control rate of 76 percent.
Early Findings with Pembrolizumab, Merck’s Investigational Anti-PD-1…
The early findings presented showed an overall response rate of 28 percent with pembrolizumab in patients with tumours that expressed PD-L1. Additionally, 48 percent of patients had stable disease, resulting in a disease control rate of 76 percent.